Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration and accommodation services for your bookings.

Educational Workshops

Educational Workshops are organized in cooperation with ESCMID Study Groups and partnering organizations. They contain review talks and/or case studies that lend themselves to discussions. The goal of this format is education through interactivity. For the first time this year, these sessions are spread over the entire duration of the congress.

Saturday 13 April 2019

08:45-12:45, Hall A
Antimicrobial susceptibility testing (AST) with EUCAST methods and breakpoints
co-organised with the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

Christian Giske (Sweden)
EUCAST news

Gunnar Kahlmeter (Sweden)
Redefining susceptibility categories and introducing areas of technical uncertainty

Johan Mouton (Netherlands)
Challenging drugs for AST: e.g. fosfomycin, polymyxins

Erika Matuschek (Sweden)
Challenging bugs for AST: e.g. H. influenzae

Matthew Ellington (United Kingdom)
Whole genome sequencing in AST: what’s new?

Qiwen Yang (China)
EUCAST around the world

Maiken C. Arendrup (Denmark)
Antifungal Subcommittee update

Interactive panel discussion


10:00-12:00, Hall I
Zoonotic species identification with MALDI-TOF MS
co-organised with ESCMID Study Groups ESGVM, ESGMD and ESGPHM

Birgitta Duim (Netherlands)
Evaluation of MALDI-TOF MS for the identification of coagulase-positive staphylococcal species within the Staphylococcus intermedius group

Belen Rodriguez-Sanchez (Spain)
Identification of “difficult bacteria” made easy

Peter Lasch (Germany)
Safety and accuracy of MALDI-TOF MS for the identification of highly pathogenic microorganisms

Interactive panel discussion


10:00-12:00, Hall E
Applying pharmacokinetic/pharmacodynamic principles in critically ill patients
co-organised with the Trainees Association of ESCMID (TAE) and the ESCMID Study Groups EPASG and ESGCIP

Elisabet Nielsen (Sweden)
Factors leading to alterations in PK/PD of antimicrobials in critically ill patients

Matteo Bassetti (Italy)
What is the type of critically ill patients at risk of multidrug resistance?

Jason Roberts (Australia)
How to optimise antibiotic administration in critically ill patients: from PK/PD to TDM

Interactive panel discussion


Sunday 14 April 2019

8:45-10-45, Hall C
Antifungal therapy: combine or not combine, this is the question!
co-organised with the ESCMID Study Groups EFISG and ESGB
Chair: Kieren Marr (United States)

Mario Fernandez Ruiz (Spain)
In vitro antifungal susceptibility and genomics to predict outcomes in fungal infections

Dimitrios P. Kontoyiannis (United States)
The case pro combination therapy
Federico Pea (Italy)
Combination antifungal treatment is usually not needed

Interactive panel discussion


13:30-15:30, Hall D
We need to improve vaccine coverage
co-organised with the French Infectious Disease Society (SPLIF)

Olivier Epaulard (France)
Vaccine hesitancy: what an ID specialist can do

Adam Finn (United Kingdom)
Vaccine policy in children

Helena Maltezou (Greece)
Vaccine policy for healthcare workers

Interactive panel discussion


13:30-18:00, Hall I
Outbreak simulation exercise: who does what and why in case of an infectious disease outbreak
co-organised with the ESCMID Study Group ESGPHM, the Trainees Association of ESCMID (TAE) and the ESCMID Task Force for Emerging Infections (EITaF)

Christian Winter (Germany)
Introduction outbreak exercise

Sergey R. Eremin (Switzerland)
Outbreak exercise

Caroline Rönnberg (Sweden)
Outbreak exercise

Alma Tostmann (Netherlands)
Outbreak exercise

Lieke B. van Alphen (Netherlands)
Outbreak exercise and result

Tim Brooks (United Kingdom)
How to get rapid access to “special diagnostics” for unusual or exotic agents?

Katrin Leitmeyer (Sweden)
Roles and responsibilities in an infectious disease outbreak

Interactive panel discussion


16:00-18:00, Hall C
Controversies in the management of hospital-acquired pneumonia

Andre Kalil (United States)
Case presentation

Ignacio Martin-Loeches (Ireland)
When pharmacokinetics and pharmacodynamics should be used for the antibiotic management of hospital-acquired pneumonias?

Antoni Torres (Spain)
What is the role of inhaled antibiotics for ventilator-associated pneumonias?

Andre Kalil (United States)
Should procalcitonin be used to de-escalate antibiotics in hospital-acquired pneumonias?

Mark L. Metersky (United States)
Can Pseudomonas ventilator-associated pneumonia be treated with 7 days of antibiotic therapy?

Monday 15 April 2019

8:45-10:45, Hall K
Update on travel vaccines and prophylaxis
co-organised with the Trainees Association of ESCMID (TAE) and the ESCMID Study Group ESGITM

Lisa Ford (United Kingdom)
Vaccines for the healthy adult traveller and the elderly or immunocompromised traveller

Martin P. Grobusch (Netherlands)
Vaccines for the pregnant traveller and the small child traveller

Patricia Schlagenhauf (Switzerland)
Malaria prophylaxis for all?

Interactive panel discussion


8:45-10:45, Hall G
How to develop guidance documents in clinical microbiology and infectious diseases

Benedikt Huttner (Switzerland)
Guidelines and other guidance documents in infectious diseases and clinical microbiology: a taxonomy and critical appraisal

Luigia Scudeller (Italy)
The GRADE system in the infectious diseases field: specific issues in the assessment of quality of the evidence

Mariska MG Leeflang (Netherlands)
From evidence to recommendations in the field of infectious disease: issues in the GRADE approach

Sheldon Stone (United Kingdom)
Proposals for adapting the GRADE approach to the clinical microbiology and infectious diseases field

8:45-10:45, Hall F
Prevention and management of tuberculosis in non-HIV-immunocompromised hosts
co-organised with the ESCMID Study Group ESGMYC

Cybele L. R. Abad (Philippines)
Prevention and management of tuberculosis in solid organ transplantation

Judith Bruchfeld (Sweden)
Prevention and management of tuberculosis associated with biologicals

Sandra Arend (Netherlands)
What do the guidelines say?

Interactive panel discussion


13:30-15:30, Hall D
Update on diagnosis and treatment of non-tuberculous mycobacteria (NTM)

Emmanuelle Cambau (France)
Diagnosis of NTM infections

Charles L. Daley (United States)
Treatment of NTM

Miguel Santin (Spain)
Challenging clinical cases of NTM

Interactive panel discussion


13:30-18:00, Hall H
Progress in Infective Endocarditis (IE)
co-organised with the ESCMID Study Group ESGBIES

José M. Miró Meda (Spain)
Endocarditis: brief overview of recent progresses and challenges

Laurens Liesenborghs (Belgium)
Staphylococcus aureus manipulates coagulation to initiate endocarditis

Bernard Iung (France)
New imaging techniques in the diagnosis of infective endocarditis

Annette Moter (Germany)
Molecular imaging after valve surgery for culture negative IE

Barbara Hasse (Switzerland)
The nightmare of Mycobacterium chimaera

Margaret Hannan (Ireland)
Diagnosis and management of infection in cardiac assist devices

Emanuele Durante Mangoni (Italy)
What's new in the antibiotic treatment of endocarditis?

Bruno Hoen (France)
What is the right timing for valve surgery in IE?

13:30-18:00, Hall G
Fast and furious in infection control: how to be successful in seven steps!
co-organised with the European Committee on Infection Control (EUCIC)

Jan A. J. W. Kluytmans (Netherlands)
The EUCIC talk: One Health approach in infection control

Nico T. Mutters (Germany)
Spotting mistakes in infection control: 67 y.o. is admitted to the hospital.

Eli Perencevich (United States)
First: build up an efficient, targeted local surveillance system

Maaike S. M. van Mourik (Netherlands)
Second: Connect surveillance data with clinical and radiological data

Walter Zingg (Switzerland)
Third: Organise information flow among infection control, antibiotic stewardship, and microbiology teams

Ben S. Cooper (Thailand)
Fourth: Planning infection control interventions using modelling and analysis of patients transfers

Sarah Tschudin-Sutter (Switzerland)
Fifth: Define goals and population for decolonisation strategies: differentiating among species and susceptibility patterns

Stephanie J. Dancer (United Kingdom)
Sixth: Infection control of the hospital environment: instruments, water, bedding, companion animals, … and now also air: what, when, and how?

Andrew James Stewardson (Australia)
Seventh: Now you are ready to demonstrate that you have been successful: how to choose your outcomes?

Interactive panel discussion


13:30-15:30, Hall C
Publishing research results: take advice with the editors
Chair: Robert C. Read (United Kingdom)

John S. McConnell (United Kingdom)
The role of journals and editors nowadays

Sharon Bloom (United States)
Journal selection: changing options and risks for authors seeking to publish

Leonard Leibovici (Israel)
Why was my article rejected?

J. Peter Donnelly (Netherlands)
Can I appeal?

Ursula Hofer (United Kingdom)
How to write an authoritative review

13:30-15:30, Hall I
Device-related central nervous system (CNS) infections
co-organised with ESCMID Study Groups ESGIAI and ESGIB

Roland Nau (Germany)
PK/PD of anti-infective agents in the CNS

Diederik van de Beek (Netherlands)
Infections associated with CSF shunts, and CSF drains

Loreen Herwaldt (United States)
Deep brain stimulation hardware-related infections

Carmen Cabellos (Spain)
Management of device-related CNS infections

13:30-15:30, Hall L
MARK SHIRTLIFF MEMORIAL SESSION
Experimental models for chronic biofilm-related infections as surrogates for clinical testing

co-organised with the ESCMID Study Group ESGB

Birthje V. Kjellerup (United States) and Thomas Bjarnsholt (Denmark)
In memoriam Mark Shirtliff

Kasper N. Kragh (Denmark)
In vitro models – from planktonic to sessile life style (when and where to settle down)

Oscar Murillo (Spain)
Foreign body related models

Kendra P. Rumbaugh (United States)
Non-foreign body related in vivo biofilm models

Interactive panel discussion

16:00-18:00, Hall K
Clinical tropical medicine: management of acute severe infection

Nicholas White (Thailand)
Severe malaria

Andrea Boggild (Canada)
Weil‘s disease

Björn Blomberg (Norway)
Haemorrhagic fever

George O. Akpede (Nigeria)
Lassa fever

Guy Thwaites (Vietnam)
Tropical brain infections


Tuesday 16 April 2019

8:45-10:45, Hall K
Challenges for clinical study designs and evidence in infectious diseases

Luigia Scudeller (Italy)
Limitations of randomised trials. Is the king naked?

Mical Paul (Israel)
Meta-analysis: friend or foe

Marc J. Bonten (Netherlands)
Innovative clinical trial designs

Interactive panel discussion

13:30-15:30, Hall C
Changing perspectives in the treatment of C. difficile infection (CDI)
co-organised with ESCMID Study Groups ESGCD and ESGHAMI

Stuart Johnson (United States)
Recent changes in CDI treatment guidelines

Maria Vehreschild (Germany)
Various forms of faecal microbiota transplantation for recurrent CDI

Tanya Monaghan (United Kingdom)
What is the target group for antitoxin treatment to prevent CDI?

Interactive panel discussion

13:30-15:30, Hall D
Neutropenia: the ups and downs of antibiotic therapy
co-organised with the ESCMID Study Group ESGICH

Monica Slavin (Australia)
Neutropenic fever and ghost-infectious diseases: no pathogens, but still antibiotics?

Genovefa Papanicolaou (United States)
Neutropenic fever and non-infectious causes: no pathogens, but still antibiotics?

Inge C. Gyssens (Netherlands)
Neutropenic fever, no pathogen, no antibiotics: is it possible?

Interactive panel discussion

 

Newsletter Sign Up

Get regular updates on ECCMID - sign up for our newsletter!